Cost savings from use of biosimilars in rheumatology

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Cost savings from use of biosimilars in rheumatology

Biosimilares/Investigación | Posted 09/08/2013 0 Post your comment

The treatment of rheumatoid arthritis provides a clear argument in favour of developing biosimilars and the need to collect sufficient pharmacological data to validate their bioequivalence and interchangeability.

The costs to society of treating rheumatoid arthritis are high. The introduction of biological disease-modifying anti-rheumatic drugs (B-DMARDs) has improved the outlook for patients not fully responding to conventional DMARDs, but they are expensive. The cost savings to be made by using less expensive biosimilar products with comparable efficacy and safety to B-DMARDs is discussed by Professors Giovanni Lapadula and Gianfranco Ferracioli [1].

In one example, use of tumour necrosis factor (TNF)-antagonists (infliximab, etanercept and adalimumab) was compared to use of conventional DMARDs, e.g. hydroxychloroquine, methotrexate, intramuscular gold, sulphasalazine and leflunomide. The results of the study showed an estimated discounted mean lifetime cost of nearly GBP 58,000 for TNF-antagonist therapy versus around GBP 21,000 for therapy with conventional DMARDs, although the TNF-antagonists produced more quality-adjusted life-years (QALYs).

This study, amongst others, highlights the huge cost savings to be made from the use of biosimilars. Lapadula notes as an example the Euros 8 billion projected savings to be made in Germany with the use of biosimilar erythropoietin.

FDA has yet to approve a biosimilar. In Europe, EMA has already approved two applications for marketing authorization of infliximab biosimilars [2, 3]. The positive decision by EMA paves the way for cheaper biosimilars to hit the market once the patents for Remicade expire, which will happen in Europe in 2014 and in the US in 2018 [4].

Related articles

Development of biosimilars for rheumatology

Biosimilars in rheumatology

References

1. Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S102-6.

2. GaBI Online - Generics and Biosimilars Initiative. Biosimilar applications under review by EMA –2013 Q1 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Aug 9]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-applications-under-review-by-EMA-2013-Q1

3. GaBI Online - Generics and Biosimilars Initiative. EMA approves first monoclonal antibody biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Aug 9]. Available from: www.gabionline.net/Biosimilars/News/EMA-approves-first-monoclonal-antibody-biosimilars

4. GaBI Online - Generics and Biosimilars Initiative. US$67 billion worth of biosimilar patents expiring before 2020 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Aug 9]. Available from: www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.